Zealand Pharma A/S (ZLDPF)
USD 113.28
(0.0%)
USD 113.28
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -330.08 Million DKK | 47.25% |
| 2022 | -625.76 Million DKK | -83.15% |
| 2021 | -341.67 Million DKK | 53.89% |
| 2020 | -740.92 Million DKK | 25.56% |
| 2019 | -995.3 Million DKK | -15.65% |
| 2018 | -860.63 Million DKK | -89.99% |
| 2017 | -452.98 Million DKK | -5182.28% |
| 2016 | 8.91 Million DKK | 108.42% |
| 2015 | -105.84 Million DKK | 60.22% |
| 2014 | -266.1 Million DKK | 7.01% |
| 2013 | -286.17 Million DKK | 20.27% |
| 2012 | -358.92 Million DKK | -28.95% |
| 2011 | -278.34 Million DKK | 27.38% |
| 2010 | -383.3 Million DKK | -165.05% |
| 2009 | -144.61 Million DKK | 31.03% |
| 2008 | -209.68 Million DKK | 12.7% |
| 2007 | -240.18 Million DKK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -6.76 Billion DKK | -2288.79% |
| 2024 Q1 | -283.21 Million DKK | 14.2% |
| 2023 FY | -330.08 Million DKK | 47.25% |
| 2023 Q3 | -268.38 Million DKK | -27.3% |
| 2023 Q2 | -210.82 Million DKK | 33.81% |
| 2023 Q1 | -318.52 Million DKK | 49.1% |
| 2023 Q4 | -330.08 Million DKK | -22.99% |
| 2022 Q1 | -333.03 Million DKK | 2.53% |
| 2022 FY | -625.76 Million DKK | -83.15% |
| 2022 Q4 | -625.76 Million DKK | -508.63% |
| 2022 Q3 | 153.13 Million DKK | 325.8% |
| 2022 Q2 | -67.81 Million DKK | 79.64% |
| 2021 Q2 | -844 Million DKK | 28.4% |
| 2021 FY | -341.67 Million DKK | 53.89% |
| 2021 Q4 | -341.67 Million DKK | 44.13% |
| 2021 Q3 | -611.56 Million DKK | 27.54% |
| 2021 Q1 | -1.17 Billion DKK | -59.1% |
| 2020 Q1 | -898.5 Million DKK | 9.73% |
| 2020 Q3 | -1.09 Billion DKK | 9.55% |
| 2020 Q4 | -740.92 Million DKK | 32.53% |
| 2020 FY | -740.92 Million DKK | 25.56% |
| 2020 Q2 | -1.21 Billion DKK | -35.13% |
| 2019 Q3 | -1.17 Billion DKK | -40.23% |
| 2019 Q1 | -956.97 Million DKK | -11.19% |
| 2019 Q2 | -837.46 Million DKK | 12.49% |
| 2019 FY | -995.3 Million DKK | -15.65% |
| 2019 Q4 | -995.3 Million DKK | 15.25% |
| 2018 Q4 | -860.63 Million DKK | 41.79% |
| 2018 Q2 | -243.58 Million DKK | 31.01% |
| 2018 FY | -860.63 Million DKK | -89.99% |
| 2018 Q1 | -353.05 Million DKK | 22.06% |
| 2018 Q3 | -1.47 Billion DKK | -507.02% |
| 2017 Q4 | -452.98 Million DKK | 28.41% |
| 2017 FY | -452.98 Million DKK | -5182.28% |
| 2017 Q3 | -632.75 Million DKK | -305.45% |
| 2017 Q2 | -156.06 Million DKK | 37.27% |
| 2017 Q1 | -248.77 Million DKK | -2891.19% |
| 2016 Q1 | -56.83 Million DKK | 46.31% |
| 2016 FY | 8.91 Million DKK | 108.42% |
| 2016 Q4 | 8.91 Million DKK | -89.81% |
| 2016 Q3 | 87.5 Million DKK | 300.43% |
| 2016 Q2 | 21.85 Million DKK | 138.45% |
| 2015 Q2 | -167.49 Million DKK | 22.2% |
| 2015 FY | -105.84 Million DKK | 60.22% |
| 2015 Q3 | -120.65 Million DKK | 27.96% |
| 2015 Q1 | -215.29 Million DKK | 19.09% |
| 2015 Q4 | -105.84 Million DKK | 12.28% |
| 2014 Q3 | -303.81 Million DKK | -2.08% |
| 2014 FY | -266.1 Million DKK | 7.01% |
| 2014 Q4 | -266.1 Million DKK | 12.41% |
| 2014 Q2 | -297.62 Million DKK | 14.88% |
| 2014 Q1 | -349.64 Million DKK | -22.18% |
| 2013 FY | -286.17 Million DKK | 20.27% |
| 2013 Q1 | -363.34 Million DKK | -1.23% |
| 2013 Q4 | -286.17 Million DKK | 14.03% |
| 2013 Q3 | -332.88 Million DKK | -2.25% |
| 2013 Q2 | -325.55 Million DKK | 10.4% |
| 2012 Q3 | -371.67 Million DKK | -14.11% |
| 2012 Q1 | -326.57 Million DKK | -17.33% |
| 2012 Q4 | -358.92 Million DKK | 3.43% |
| 2012 Q2 | -325.72 Million DKK | 0.26% |
| 2012 FY | -358.92 Million DKK | -28.95% |
| 2011 FY | -278.34 Million DKK | 27.38% |
| 2011 Q3 | -291.83 Million DKK | 1.41% |
| 2011 Q1 | -240.48 Million DKK | 37.26% |
| 2011 Q2 | -296.02 Million DKK | -23.09% |
| 2011 Q4 | -278.34 Million DKK | 4.62% |
| 2010 Q4 | -383.3 Million DKK | 0.0% |
| 2010 FY | -383.3 Million DKK | -165.05% |
| 2009 FY | -144.61 Million DKK | 31.03% |
| 2008 FY | -209.68 Million DKK | 12.7% |
| 2007 FY | -240.18 Million DKK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 28667.831% |
| CSL Limited | 10.52 Billion USD | 103.136% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 2194.024% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 8115.519% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 82240.555% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 871.343% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | -5135.621% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 35700.3% |
| Mesoblast Limited | 55.85 Million USD | 690.926% |
| Marizyme, Inc. | 18.56 Million USD | 1877.589% |
| Genus plc | 190.6 Million USD | 273.18% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 14863.229% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 27292.047% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 48641.324% |
| ContraFect Corporation | -6.02 Million USD | -5377.614% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 245260.02% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| IMV Inc. | 7.67 Million USD | 4403.241% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 6099.405% |
| MultiCell Technologies, Inc. | 90.04 USD | 366593836.117% |
| Accustem Sciences Inc. | -733.97 Thousand USD | -44871.511% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 2649.676% |
| EV Biologics, Inc. | 1.36 Million USD | 24229.24% |
| Q BioMed Inc. | 4.06 Million USD | 8230.058% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 1180.32% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 32855.36% |
| Biomind Labs Inc. | 711.4 Thousand USD | 46498.661% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 2677.431% |
| Skye Bioscience, Inc. | -5.72 Million USD | -5669.246% |
| SQZ Biotechnologies Company | -36.23 Million USD | -810.87% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 236202.687% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 5943.828% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 14821.084% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | 1661553.667% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 53136.647% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 109.8 Million USD | 400.609% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 38470.759% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 15090.184% |
| GB Sciences, Inc. | 1.74 Million USD | 18990.744% |
| Alpha Cognition Inc. | -183.78 Thousand USD | -179498.777% |
| argenx SE | -2.02 Billion USD | 83.731% |
| HST Global, Inc. | 96.79 Thousand USD | 341117.429% |
| Halberd Corporation | 144.72 Thousand USD | 228180.928% |
| Enzolytics Inc. | 981.65 Thousand USD | 33724.915% |
| Resverlogix Corp. | 6.45 Million USD | 5216.742% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | -48939.726% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 859.96% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 645.176% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | -602.121% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 16609.069% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 4768.114% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 91863.087% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 12286.339% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | -3633.985% |
| AVAX Technologies, Inc. | -5.9 Million USD | -5491.554% |
| ONE Bio Corp. | 9.04 Million USD | 3751.324% |
| Zenith Capital Corp. | 10.06 Thousand USD | 3279919.157% |
| Genscript Biotech Corporation | -1.06 Billion USD | 68.899% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 164784.781% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 13933.877% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 200746.165% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | -1801848.903% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 160164.883% |
| Agentix Corp. | 37.63 Thousand USD | 877251.816% |
| Adynxx, Inc. | - USD | Infinity% |
| Kadimastem Ltd | -253.1 Thousand USD | -130314.22% |
| Helix BioMedix, Inc. | -2.57 Million USD | -12743.459% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 1727.939% |
| BioStem Technologies, Inc. | 4.47 Million USD | 7481.042% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 164112.144% |
| Burzynski Research Institute, Inc. | -1310.00 USD | -25196922.901% |
| LadRx Corporation | -2.03 Million USD | -16108.496% |
| Cell Source, Inc. | 9.23 Million USD | 3675.412% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | -1617309.839% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 52067.593% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 52067.593% |
| NovAccess Global Inc. | 2.17 Million USD | 15251.999% |
| Affymax, Inc. | -5.59 Million USD | -5797.463% |
| Itoco Inc. | 228.3 Thousand USD | 144678.962% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 242826.25% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 6758.886% |
| CytoDyn Inc. | 20.26 Million USD | 1729.064% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | -51017056.105% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | -3561282.081% |
| Qrons Inc. | 351.42 Thousand USD | 94025.908% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 4383.427% |
| SYBLEU INC | 473.71 Thousand USD | 69779.385% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | -132133.395% |
| Rebus Holdings, Inc. | 305 Thousand USD | 108323.279% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 7505.864% |
| Mobile Lads Corp. | 484.23 Thousand USD | 68265.879% |
| International Stem Cell Corporation | 2.59 Million USD | 12844.44% |
| Bioxytran, Inc. | 1.89 Million USD | 17482.62% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 528965.781% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 15235.082% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 9712.143% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 3959.242% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 42823.014% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | -26306.48% |
| Neutra Corp. | 52.18 Thousand USD | 632596.599% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | -13161.591% |
| PureTech Health plc | -167.19 Million USD | -97.42% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | -134677.549% |
| IXICO plc | -4.44 Million USD | -7326.584% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 2597.019% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 701.778% |
| CSL Limited | 10.52 Billion USD | 103.136% |
| Cellectis S.A. | -43.81 Million USD | -653.285% |